Switzerland's Idorsia 9M revenue flat, QUVIVIQ sales up 54%

Overview

• Swiss biopharma firm's 9M 2026 revenue was flat yr/yr at CHF 172 mln

• QUVIVIQ sales rose 54% yr/yr to CHF 142 mln in first nine months

• Net loss widened to CHF 206 mln, mainly due to higher financial and operating expenses

Outlook

• Idorsia reaffirms full-year 2026 guidance with improved US GAAP operating loss outlook

• Company expects full-year 2026 QUVIVIQ sales of CHF 200 mln

• Company lowers 2026 US GAAP operating loss forecast to about CHF 140 mln from CHF 160 mln

Result Drivers

• QUVIVIQ GROWTH DRIVERS - Co cited accelerating demand, geographic expansion, broader patient access, increased primary care penetration, and lifecycle expansion opportunities as key drivers of QUVIVIQ sales growth

• HIGHER COST OF SALES - Co said increased cost of sales was driven by higher product sales

• WIDER LOSS - Loss widened to CHF 206 mln, which co attributed to higher financial and operating expenses

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Idorsia Ltd is CHF5.50, about 19.8% above its October 28 closing price of CHF4.59

Reuters Recommended Reads

• Oct 28 - Sweden's BioInvent Q3 net sales rise but loss narrows

• Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength

• Oct 28 - Finland's Orion Q3 sales rise 28%; upgrades 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)